^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Title:

Health Canada Approves Biocon and Mylan’s Ogivri™, the First Trastuzumab Biosimilar, for the Treatment of HER2-Positive Breast and Gastric Cancers

Published date:
05/22/2019
Excerpt:
Biocon Ltd. and Mylan N.V. today announced that Health Canada has approved Mylan’s Ogivri™ (trastuzumab), a biosimilar to Herceptin1 (trastuzumab) co-developed with Biocon, for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma).
Evidence Level:
Sensitive: A1 - Approval
Published date:
12/12/2018
Excerpt:
Ogivri should only be used in patients with metastatic gastric cancer (MGC) whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result.
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
Ogivri is a HER2/neu receptor antagonist indicated for...the treatment of HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.